---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-024979"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2025-08-20T23:59:59+00:00"
generated_at: "2026-05-17T11:10:17.215054+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics reports Q2 2025 revenue $3.8M, operating loss $4.9M; acquired Sleep Center of Nevada

## Summary
- Q2 2025 revenue $3.8M vs $4.1M YoY; gross margin fell to 55% from 65%.
- Operating loss widened to $4.9M from $1.9M; expenses up 52% on acquisition-related costs.
- Cash at June 30, 2025 was $4.4M, down from $6.2M at December 31, 2024.
- Acquired Sleep Center of Nevada on June 10; generated ~$500k diagnostic revenue in 20 days with demand exceeding capacity.
- Entered management agreement with MISleep Solutions for Michigan center; opening expected October 2025.

## SEC filing metadata
- accession: 0001641172-25-024979
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2025-08-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000164117225024979/0001641172-25-024979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000164117225024979/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-024979
- JSON: https://secwatch.observer/filing/0001641172-25-024979.json
- Plain text: https://secwatch.observer/filing/0001641172-25-024979.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.